ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Kyowa Kirin invests in MEI Pharma’s blood-cancer drug

by Ryan Cross
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

The Japanese drugmaker Kyowa Kirin will pay San Diego–based MEI Pharma $100 million up front and up to $583 million in milestone payments to develop and commercialize its experimental blood-cancer drug, MEI-401. The compound, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, is being tested in a Phase II study of follicular lymphoma and a Phase I study of B-cell malignancies. The firms will split costs and profits in the US, while Kyowa Kirin has exclusive rights to the drug everywhere else.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment